Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis

D. E. Meyers, B. Adu-Gyamfi, A. M. Segura, L. M. Buja, H. R. Mallidi, O. H. Frazier, L. Rice

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

We describe a patient who underwent a successful heart and kidney transplant for light-chain amyloidosis. She had an excellent hematologic response to bortezomib/dexamethasone therapy. Follow-up therapy with lenalidomide was started, and the patient quickly had a fatal allograft rejection of the heart and kidney. We present evidence to support the theory that lenalidomide, a known immunomodulator, may have stimulated the immune system and precipitated the fatal rejection episode. The authors report the case of a 68-year-old woman who underwent a successful combined heart and kidney transplant for amyloidosis, was then started on lenalidomide therapy, and died 2 weeks later, likely because of lenalidomide-related severe rejection of both organs.

Original languageEnglish (US)
Pages (from-to)2730-2733
Number of pages4
JournalAmerican Journal of Transplantation
Volume13
Issue number10
DOIs
StatePublished - Oct 2013
Externally publishedYes

Keywords

  • Allograft rejection
  • amyloidosis
  • cardiac transplant
  • lenalidomide
  • renal transplant
  • transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis'. Together they form a unique fingerprint.

Cite this